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I must finish what I’ve started, even if,
inevitably, what I finish turns out not to be
what I began.
Salman Rushdie, Midnight’s Children.
ABSTRACT
Several hormonal systems are disrupted in chronic kidney dis-
ease (CKD) and disturbances of the growth hormone axis could
contribute to increased morbidity and mortality through effects
on cardiovascular health, energy metabolism and inflammation.
The overall aim of this thesis was to increase knowledge about
hormonal alterations and their consequences in CKD, focusing
on cardiovascular disease (CVD), mortality and the growth hor-
mone axis in end-stage renal disease. We tested cross-sectional
associations between different growth hormones and known risk
factors for CVD. We also analyzed longitudinal associations be-
tween blood hormone levels and outcomes. In addition we studied
potassium disturbances in a large healthcare-based cohort.
Paper I was a cohort study of insulin-like growth factor 1 (IGF-1)
levels and mortality in patients starting hemodialysis. We found
that patients with IGF-1 levels in the lowest tertile were more
often female, had lower creatinine, lower serum albumin and higher
degree of inflammation. Low IGF-1 levels were associated with
increased mortality and this association remained when adjusted
for age, sex and comorbid conditions [diabetes mellitus (DM),
CVD, heart failure]. Our results show that low IGF-1 levels at
dialysis initiation are associated with increased mortality.
Paper II was a cohort study of incident dialysis patients in-
vestigating pregnancy-associated plasma protein-A (PAPP-A) in
relation to mortality and CVD. We also tested whether body
composition, DM or inflammation would act as effect modifiers on
this association. Higher PAPP-A levels showed a moderate associ-
ation with mortality when adjusted for cardiovascular risk factors
and body composition but when also including high-sensitivity
C-reactive protein (hs-CRP) the association was weakened. In sur-
vival analysis, interactions with PAPP-A were found for hs-CRP,
DM and fat tissue index. This indicates that higher PAPP-A
levels in patients starting dialysis are associated with increased
mortality, and that this association is modulated by inflammation,
DM and body composition.
In paper III we describe incidence and determinants of hyper-
kalemia and hypokalemia in a large healthcare based cohort in-
cluding adult individuals from Stockholm accessing healthcare in
2009. Estimated glomerular filtration rate (eGFR) was included
as a measure of kidney function. During three years follow-up,
13.6% had at least one episode of hypokalemia. Hyperkalemia of
any degree of severity was detected in 7%. Frequency of potas-
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sium testing was naturally associated with dyskalaemia risk. In
adjusted analysis, lower hyperkalemia risk was seen in women
and in loop/thiazide diuretics users while hyperkalemia risk was
higher in older age, lower eGFR, diabetes, heart failure and use
of renin-angiotensin-aldosterone system inhibitors. Women, those
of younger age, with higher eGFR or use of diuretics had higher
risk of hypokalemia.
In paper IV, we investigated PAPP-A levels and mortality in
prevalent HD patients and sought specifically to test our previous
exploratory findings that inflammation and DM modulated the
effect of PAPP-A on mortality. Higher PAPP-A was associated
with increased mortality both in univariable analysis and when
adjusted for confounders and cardiovascular risk factors. An
interaction between PAPP-A and DM was found, implying greater
prognostic utility of PAPP-A in patients with DM.
In paper V, we hypothesized that combining a function mea-
surement of muscle strength (handgrip strength, HGS) with a
biochemical nutritional marker (plasma IGF-1 levels) would have
a stronger association to mortality in CKD than either marker
alone. Patients in the low IGF-1 and low HGS category had
increased mortality rate compared to the other categories and this
association was robust when adjusted for Framingham’s CVD risk
score, CVD, malnutrition, smoking, hs-CRP, albumin and lean
body mass index. The predictive utility of IGF-1 was somewhat
enhanced but still weak in the low HGS group. Our results in-
dicate that low HGS predicts higher mortality risk in CKD and
that adding IGF-1 levels may marginally improve risk prediction
in the low HGS group.
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Chapter 1
Background
1.1 Introduction
The focus of this chapter is the growth hormone (GH)/insulin-like
growth factor 1 (IGF-1) axis in chronic kidney disease (CKD),
specifically components of this system that we have investigated
in the thesis papers. A brief vignette exemplifying hormonal
alterations in CKD is given, along with reflections on biomarkers
in general and the challenge of utilizing them in research con-
cerning end-stage renal disease (ESRD). A section on potassium
dysequilibrium is also included.
CKD is defined as “abnormalities of kidney structure or function,
present for >3 months, with implications for health” [1]. Causes
of CKD include for example diabetes mellitus (DM), hypertension
and inflammatory renal diseases. If renal function deteriorates
and reaches ESRD, continued renal replacement therapy is needed
[2]. Dialysis, either hemodialysis (HD) or peritoneal dialysis (PD),
is usually selected as the initial renal replacement therapy and
renal transplantation performed for some patients at a later time
[3]. CKD can cause alterations in bone, brain, heart, vascula-
ture and other organs [4], as well as dysregulation of acid-base
homeostasis and electrolytes such as potassium [5,6]. CKD and
especially ESRD is therefore associated with increased mortal-
ity and morbidity [5,7]. Importantly, CKD is associated with a
dramatic increase in cardiovascular disease (CVD). To illustrate
this, Figure 1.1 shows the incidence of cardiovascular events in
different degrees of kidney failure, based on results from Go et
al [8]. Note that patients on dialysis or renal transplant were
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Figure 1.1: Age-Standardized Rates of Cardiovascular Events in
renal failure
excluded.
1.2 Causes of hormone dysequilibrium
in CKD
Several hormonal systems are dysregulated in CKD. Well known
examples include a relative deficiency of erythropoetin in renal ane-
mia [9] and elevated parathyroid hormone levels due to retention
of phosphate, hypocalcemia and decreased 1,25-dihydroxyvitamin
D production [10]. The mechanisms by which endocrine alter-
ations appear in CKD are diverse. For example, stimulation
or inhibition of hormone synthesis can be seen for parathyroid
hormone (PTH) [10] and erythropoetin [9], respectively. Post-
translational modifications also affect PTH signalling, leading
to altered effect on the hormone receptor [11]. Accumulation of
hormones or hormone fragments due to reduced renal clearance
is yet another way in which CKD alters hormone homeostasis,
exemplified by retention of PTH fragments [11] and decresed
clearance of prolactin (PRL), the latter leading to secondary dys-
regulation of other sex hormones [12]. PRL also exemplifies the
disturbance of normal pulsatile secretion that is present for many
pituitary hormones, in that elevated PRL inhibits the rhythmicity
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Table 1.1: Example mechanisms of hormonal dysregulation in
CKD
Effect on hormone Mechanisms
Synthesis Inhibition
Stimulation
Post-translational modifications
Release Stimulation
Inhibition
Rythmicity
Transport Altered levels of hormone binding proteins
Altered function of hormone binding proteins
Degradation and elimination Proteolysis
Reduced glomerular filtration
Action on receptor Receptor number
Resistance
Local sequestration/release
Intracellular action Alteration of intracellular pathways
of gonadotropin-releasing hormone, with secondary effects on sex
hormone secretion. Alterations of hormone transport can also
occur in renal failure. IGF-1, which mediates growth hormone
effects, binds to a number of different IGF-1 binding proteins
(IGFBPs). Retention of these binding proteins affects hormone
availability, -degradation and -action [13]. Finally, the effect of a
hormone on its target tissue is influenced by receptor density and
intracellular pathways, mechanisms which are also disturbed in
IGF-1 signalling in CKD [14]. Example mechanisms of hormonal
dysregulation in CKD are listed in Table 1.1.
1.3 The growth hormone/insulin-like
growth factor 1 axis
GH is secreted from the anterior pituitary, regulated by neuroen-
docrine mechanisms including stimulatory GH-releasing hormone
(GHRH) and inhibitory somatostatin (SS), both originating from
the hypothalamus [15]. Historically, it was postulated that the
effect of GH on skeletal muscle was mediated by some other sub-
stance [16], later isolated and termed “Somatomedin” [17], further
characterized as “nonsuppressible insulin-like activity” [18] and
named insulin-like growth factor (IGF) [19]. It has later been
found that GH also has direct effects apart from those mediated
through IGF-1 and that IGF-1 has both auto- and paracrine
functions [20]. Further, there are two types of IGFs, IGF-1 and
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IGF-2, that bind with different affinity to the IGF-1 receptor,
although GH action is mediated primarily by IGF-1 [20]. GH
induces production of its effector hormone in multiple tissues, but
the liver is the main source of circulating IGF-1 [21,22].
Several IGFBPs have been identified [23]. These prevent degra-
dation and elimination of IGF-1, providing a plasma pool of the
bound hormone, and interact in a complex manner to regulate
local IGF-1 availability [24]. Paracrine IGFBPs sequester IGF-1,
which can be made available to the target tissue through prote-
olysis of the IGF-1-binding protein complex [25]. Intriguingly,
it has been found that IGFBPs also have diverse IGF-1 inde-
pendent functions [26–28]. For example, IGFBP1 promotes cell
migration [29] and IGFBP-3 has IGF-1 independent effects on
cell growth [28]. Locally, IGF-1 action is also regulated by the
membrane bound matrix metalloproteinase pregnancy-associated
plasma protein-A (PAPP-A), which cleaves IGFBP-4 and thereby
releases IGF-1 from its binding protein, making it available to
the IGF-1 receptor at the target cell surface [25]. IGF-1 acts
on most cell types and has both mitogenic and anti-apoptotic
effect [28], typically inducing hypertrophy and hyperplasia [30].
Apart from regulating growth during adolescence, GH and IGF-1
have multiple other actions in adults, including effects on energy
metabolism [31], bone metabolism [32] and on the cardiovascular
system [33]. Further, reduced IGF-1 signalling has been associated
with longevity in a number of organisms [34].
A concept of reduced levels of “free” IGF-1 has been suggested [14],
where elevated IGFBP-levels would lead to lower concentrations
of unbound IGF-1 and thereby decreasing IGF-1 signalling. This
can be challenged, however, since IGFBPs can also enhance IGF-1
action [13,35]. In addition, there is a substantial local IGF-1
production and -regulation [36]. Thus, disturbances in IGFBP
levels are not easily interpreted in terms of reduced or increased
IGF-1 signalling in the target tissues.
1.3.1 Pregnancy-associated plasma protein-A
PAPP-A is a membrane bound matrix-metalloproteinase which
cleaves IGFBPs 3-, 4- and 5 and thereby releases IGF-1 from
its binding protein, making it available to the IGF-1 receptor at
the target cell surface [37]. A second form of PAPP-A, named
PAPP-A2, has also been identified. It has proteolytic activity on
IGFBPs 3- and 5 but IGFBP4 is specifically cleaved by PAPP-A
[38]. Since IGFBPs have higher affinity than the IGF-1 receptor
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for IGF-1, proteolysis of the IGFBPs increases IGF-1 activity
on the receptor. Enzymes like PAPP-A that exhibit proteolytic
activity against IGFBPs are therefore important regulators of
IGF-1 action [39]. The role of PAPP-A in regulating growth is
supported by animal experiments. For example overexpression of
PAPP-A has anabolic effect on muscle in mice [40] while PAPP-A
knock-out mice exhibit reduced IGF1 activity, primarily in the
kidney [41]. Modulating PAPP-A expression also affects bone
growth [42] and muscle function [43].
PAPP-A is expressed in most tissues, with the highest abundance
in kidney, bone and placenta [44]. During pregnancy PAPP-A is
synthesized in placental tissue and complex-bound to the proform
of eosinophil major basic protein. Elevation of non-complexed
plasma PAPP-A in other conditions may represent up-regulation of
tissue expression, induced by injury or inflammation, and increased
escape of otherwise membrane-bound PAPP-A into the circulation
[25]. A number of regulators of PAPP-A synthesis and -activity
have been identified. PAPP-A is affected in inflammatory injury
responses and tissue remodeling [44], where PAPP-A expression
is stimulated by tumor necrosis factor (TNF) and interleukin-1b
(IL-1b) and inhibited by interferon gamma and stanniocalcin-
2. It should be noted that PAPP-A regulation by cytokines
may be cell-specific. For example, in vascular smooth muscle
cells, IL-1b is more potent than TNF in stimulating PAPP-A
expression. However, the opposite has been demonstrated in
human coronary artery endothelial cells, in which IL-1b has a
weaker stimulatory effect than TNF [45]. There is some evidence
of interaction between PAPP-A and other hormonal systems.
Induction of PAPP in acute phase response may be dependent on
sex hormones with progesterone in females and oestradiol in males
being permissive of PAPP increase while testosterone inhibits
PAPP-elevation in response to injury [46]. Further, PTH inhibits
PAPP-A activity in vitro and this suppression is alleviated by
estradiol [47]. However, early studies on PAPP-A are limited by
polyspecific antibodies obtained from immunization with purified
protein from plasma, which may recognize both PAPP-A and
pro-myelin basic protein, and should therefore be interpreted with
caution [25].
To summarize, PAPP-A regulates local IGF-1 action and may be
up-regulated in pathological conditions such as tissue inflamma-
tion.
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1.3.2 GH/IGF-1 axis and cardiovascular dis-
ease
The presence of GH-receptors in heart and vasculature indicates
that the GH-IGF1-axis has effects on these systems. In experimen-
tal models, GH and IGF-1 induces cardiac myocyte hypertrophy
and enhance cardiac contractility [48,49]. Conditions with GH
excess or -deficiency are associated with CVD and CVD-related
mortality [50,51] and in the general population, both high and low
IGF-1 levels associate to increased cardiovascular mortality [52].
On the basis of its mitogenic effect on smooth muscle cells, it has
been proposed that IGF-1 promotes development of atheroscle-
rotic lesions [53] and the finding of IGF-1 and IGFBP expression
in human atherosclerotic plaques suggested that these play a role
in coronary artery disease [54]. In apparent conflict with this
hypothesis, low IGF-1 levels are also associated with increased
risk of ischemic heart disease [55]. Further, in a study on Apo E
knock-out mice, treatment with an IGF-1 analog reduced carotid
stenosis as well as signs of plaque instability such as cap to core
ratio and rate of intraplaque hemorrhage [56]. Others have found
that the beneficial effect from IGF-1 may be mediated through
anti-inflammatory effects on the vasculature, with reductions in
both interleukin-6 (IL-6) and TNF expression [57]. Thus, it is
not clear if IGF-1 activity promotes or inhibits atherosclerosis
and there may be differential effects on development of arterial
stenosis and plaque instability, respectively.
In rodent models, lower PAPP-A activity has been associated
with longer lifespan, less vascular cell proliferation after injury,
reduced plaque area and less luminal occlusion as well as inhibited
atherosclerotic plaque progression in atherosclerosis [41,58]. In a
study by Harrington et al atherosclerosis-prone mice with deletion
of the PAPP-A gene were generated [59]. While the mice retain-
ing PAPP-A expression had progression of atherosclerotic lesion
area, with increases in PAPP-A, IGF-1 and IGFBP-4 mRNA in
these lesions, the PAPP-A knock-out mice had less progression of
atherosclerosis and lower IGF-1 activity in aortic tissue. Increased
PAPP-A activity has in rodents been linked to vascular smooth
muscle cell proliferation and atherosclerosis [60]. An increased
plasma PAPP-A concentration is associated with extent of coro-
nary artery disease in humans, as well as with mortality in chronic
stable angina pectoris and acute coronary syndromes [61]. An
interaction between PAPP-A and the anti-inflammatory cytokine
interleukin-10 (IL-10) levels has been observed, indicating that
elevated PAPP-A is associated with worse outcomes only when IL-
6
10 levels are low. Increased PAPP-A levels have also been linked
to carotid- and peripheral artery disease [61,62]. Sangiorgi et al
analyzed PAPP-A in atherosclerotic lesions removed at endarterec-
tomy [63]. They found that both serum levels and expression of
PAPP-A was higher in vulnerable plaques compared to stable ones.
Others have found that PAPP-A levels are inversely associated
with plaque thickness, but positively correlated with echogenicity
and plaque inflammation [61].
The GH-IGF-1 axis may also be linked to cardiovascular disease via
effects on energy metabolism and the metabolic syndrome [31,64].
GH affects protein metabolism, increases lipolysis and glucose
output from the liver [31] and among other features, persons with
GH deficiency exhibit central adiposity and decreased muscle
mass [65]. In a randomized controlled trial of GH treatment
in postmenopausal women with abdominal obesity, Franco et al
showed that GH reduced abdominal visceral fat and improved
insulin sensitivity as well as reducing low-density lipoprotein (LDL)
concentrations [66]. In line with these associations between GH
and metabolic profile, lower serum IGF-1 levels are associated
with an increased prevalence of insulin resistance and risk factors
for metabolic syndrome in nondiabetic persons [67] and IGF-1
treatment increases insulin sensitivity in type 2 DM [68].
1.3.3 Links to body composition, malnutrition
and inflammation
In line with the influence of GH-IGF on energy metabolism de-
scribed above, these hormones also affect body composition [69].
GH has protein anabolic effects and preserves muscle mass in
the fasting state [70]. Persons with GH deficiency exhibit central
adiposity and decreased muscle mass [65]. In a study on adult
onset GH deficiency, Bengtsson et al investigated the effects of
recombinant GH on body composition [71] and found that GH
treatment reduced body fat and that visceral fat was reduced more
than subcutaneous fat. Also, GH treatment increased muscle vol-
ume, increased serum phosphate and reduced PTH and thyroxine
levels. In turn, body composition and nutritional factors can also
influence the GH-IGF-1 axis. GH production rate and frequency
of pulsatility is reduced in obesity [72] and undernutrition causes
GH resistance with lower IGF-1 levels and elevated GH [73,74].
Consequently, IGF-1 levels correlate with nutritional markers such
as triceps skinfold thickness [75]. PAPP-A is also related to body
composition. It is more abundantly expressed in visceral- than in
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subcutaneous fat and in PAPP-A knock-out mice mesenteric fat
depots are reduced [76]. Thus, there is evidence of a bidirectional
link between fat tissue and PAPP-A. In ESRD, there is a negative
association between PAPP-A and body mass index (BMI) and a
link to protein-energy wasting (PEW) has been suggested [77].
The concept of PEW describes loss of protein mass and energy
stores [78] and is common in hemodialysis [79]. Notably, surrogate
markers for PEW are associated to CVD and increased mortality.
Hypoalbuminemia is viewed as a marker of PEW, but its utility
as a biomarker is limited since it is affected by inflammation and
urinary losses [80–82]. Compared to albumin, IGF-1 correlates
more strongly to biochemical- and anthropometric markers of
PEW and malnutrition [83]. In ESRD, IGF-1 activity is thought
to be reduced due to increased levels of IGF-1 binding proteins
(IGFBP’s) as well as altered receptor- and post-receptor signaling
[84]. These GH/IGF-1-axis disturbances may contribute to PEW
in ESRD.
The growth hormone axis interconnects with inflammatory path-
ways. A number of different inflammatory mediators, such as
interleukin-1, TNF, and IL-6, can modulate the effects of IGF-1
on target tissue [85] and conversely, IGF-1 infusion has been found
to reduce vascular expression of IL-6 and TNF, as well as reducing
markers of oxidative stress [57]. Further, GH replacement in GH
deficiency reduces inflammatory markers c-reactive protein (CRP)
and IL-6 [86]. Chronic inflammation is thought to cause GH-axis
dysregulation through multiple mechanisms, including changes in
IGFBP levels and disrupted intracellular signalling pathways [87].
There is also evidence of an interaction between IGF-1 levels and
inflammation on nutritional parameters [88].
1.3.4 GH/IGF-1 axis dysregulation in CKD
In CKD, the GH-IGF-1 is dysregulated in multiple ways [14].
Although animal experiments have shown that stimulation of GH
release via GHRH from the hypothalamus may be reduced in renal
failure [89], the daily secretion rate of GH is elevated in uremic
patients [90] and GH is eliminated to a large extent through the
kidneys [91]. Veldhius et al found that GH half life was prolonged
in uremic patients compared to controls, with a half life of 17 ±1.4
minutes in controls versus 21 ±1.3 minutes in uremia [90], and
that GH pulsatility was at a higher frequency in uremia. Others
have confirmed that metabolic clearance of GH is determined by
glomerular filtration rate (GFR) and plasma concentration of the
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hormone [92]. GH is ultrafiltrated in the kidney and to a large
extent absorbed by endocytocis into the tubular cells where it
undergoes proteolysis. IGF-1 on the other hand, is not filtered to
any significant extent by the kidneys [93]. The pattern of hormone
levels in CKD suggest a state of GH resistance, with reduced
levels of IGF-1 and normal or elevated GH [94,95]. Tönshoff et
al studied GH and IGF-1 levels in children with pre-terminal
or end-stage renal disease and found that while GH levels were
increased in children with CKD, IGF-1 levels were not elevated
compared to controls, indicating that IGF-1 producing tissues did
not respond to GH stimuli [96]. Reduced IGF-1 expression has
been demonstrated in some tissues in uremic rats [97] and uremic
serum has reduced IGF-1 activity [98]. Several perturbations
may contribute to GH resistance in CKD, for example altered
IGFBP levels [99], reduced GH receptor density [97], and impaired
post-receptor signalling [100].
Chronic inflammation is common in ESRD and contributes to GH-
axis dysregulation as noted above. In addition, down-regulation
of GH- and IGF-1 receptors in inflammation and uremia has been
hypothesized [87,97]. However, there is some evidence to the
contrary and in a study on 21 ESRD patients with 14 controls,
Greenstein et al found no difference in GH receptor expression
between the groups [101], although GHBP levels were reduced in
uremia and correlated to the inflammatory marker CRP.
To summarize, GH axis disturbances could contribute to increased
morbidity and mortality in ESRD through effects on cardiovascular
health, energy metabolism and inflammation, or serve as markers
associated with these conditions.
1.4 GH-IGF-1 axis hormones as
biomarkers in ESRD
As described above, the GH axis dysregulated in CKD and linked
to CVD, PEW and inflammation, conditions that are prevalent
in ESRD and contribute to increased mortality in this population
[102]. Components of the GH-IGF-1 axis that are possible to
measure in blood could therefore be suitable candidate biomarkers
for PEW and CVD as well as for predicting mortality in ESRD
patients. Although GH levels in blood are difficult to assess due
to pulsatility and diurnal variation, IGF-1, IGFBPs and PAPP-A
are not subject to these limitations.
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Table 1.2: Characteristics of cohort studies on IGF-1 and mor-
tality in dialysis
Author Year Population N
Himmelfarb 1994 Prevalent HD 52
Fernandez-Reyes 2002 Prevalent HD 64
Qureshi 2002 Prevalent HD 128
Hung 2005 Prevalent HD 158
Kalousova 2012 Prevalent HD 261
Beberashvili 2013 Prevalent HD 96
Jia 2014 Incident HD/PD 365
Nilsson 2016 Incident HD 265
GH has not been evaluated as a risk marker for mortality in ESRD.
It has however been used in treatment studies with mortality as
end-point. Kopple et al conducted a RCT of GH treatment in
HD patients [103]. The study was terminated early due to slow
recruitment and no subjects completed the planned 24 month
treatment period. However, 712 patients were randomized and 695
received at least one dose of recombinant human GH (hGH). There
was no effect of treatment on all-cause mortality, cardiovascular
events or the combination of these two outcomes. Interestingly, a
reduction of hs-CRP was seen with treatment, as well as effects
on body composition, with reduction in body weight and total
body fat, although there was no change in lean body mass.
The association of IGF-1 to outcomes in ESRD has been investi-
gated in a few relatively small studies. Characteristics of these
studies is presented in Table 1.2.
A summary of results from the same studies is presented in Table
1.3. Note that in the studies by Hung et al [104] and Nilsson et
al [105], the risk associated with the low IGF-1 is shown, while
others presented the (reduced) risk associated with high IGF-1.
1.4.1 Himmelfarb 1994
In 1994, Himmelfarb et al investigated nutritional parameters in-
cluding IGF-1 in 52 prevalent HD patients (mean age 65 years, 48%
male, 44% with diabetes) and found that low dialysis adequacy
(Kt/V) and high cortisol but not IGF-1 levels were predictive of
mortality [106]. A multivariable Cox proportional hazards model
was used, including the parameters kt/V, serum albumin, predial-
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Table 1.3: Summary of results from cohort studies on IGF-1
and mortality in dialysis
Author Crude model Adjusted model
Himmelfarb 1994 - OR not presented (P 0.2)
Fernandez-Reyes 2002 - OR 0.98-0.99
Qureshi 2002 Log rank P <0.01 -
Hung 2005 NS (t-test survivors) OR 0.47-5.43†
Kalousova 2012 HR 0.532-0.814 -
Beberashvili 2013 HR 0.73-3.07 HR 0.53-2.81
Jia 2014 HR 0.31-0.57 HR 0.32-0.98 per SD
Nilsson 2016 OR 1.7–3.4† OR 1.1-2.4†
† Odds ratios for lowest IGF-1 tertile.
ysis cortisol, IGF-1, triceps skin-fold thickness (TSFT), mid-arm
circumference (MAC), the latter two treated as continuous vari-
ables. The authors used stepwise backward elimination to identify
important predictors of outcome (hospitalization, death). How-
ever, it is not clear from the paper which variables were eliminated
by this procedure and all variables listed above were included in
the final model. Follow-up was 12 months and outcomes were
hospitalization (n = 35) and death (n = 14), respectively. No-
tably, serum albumin was not associated to any of the outcomes
in this study. IGF-1 levels were found to be higher in HD patients
compared with age- and sex matched controls (178 ± 9 ng/mL vs
142 ± 58 ng/mL, t-test p ≤ 0.05). Also, postdialysis IGF-1 levels
were elevated compared to predialysis values (217.8 ± 13.5, p ≤
0.05). IGF-1 was not correlated with nutritional parameters in
this study (mentioned in the discussion section - data not shown).
A major limitation, emphasized by the authors, is the small sample
size. In survival analysis, a low number of events per variable
in multivariable models increases the risk of type I and type II
error [107]. A rule of thumb is a minimum of 10-20 events per
variable [108], although it has been argued that this rule can
be relaxed in certain circumstances, for example in sensitivity
analysis when demonstrating adequacy of control for confounding
[109]. In the study by Himmelfarb et al, there were 14 deaths and
six covariables (again, it is not clear from the article if all six were
entered into the final cox model or if some were eliminated through
backwards exclusion), yielding 2.3 events per variable (5.8 for
hospitalizations). In addition, potentially important confounders
such as sex, age and concomitant diabetes were not considered.
Thus, the risk of error as well as residual confounding must be
considered high in this analysis.
11
1.4.2 Fernandez-reyes 2002
In a marginally larger study (N = 64), Fernandez reyes et al [110]
studied IGF-1 as a predictor of mortality in prevalent HD patients.
Nutritional and inflammatory parameters such as albumin, CRP,
BMI, TSF, MAC and mid-arm muscle circumference (MAMC)
were measured.
IGF- levels were at 194 ± 110 ng/mL (range 23-551). IGF-1
levels were lower in those with higher CRP values (t-test p-value
= 0.02) but the association was not statistically significant in a
multivariable adjusted logistic regression model. Using Pearson
correlation coefficient IGF-1 was associated with age, albumin
and cholesterol. Cox proportional hazards models were used for
analyzing mortality rate, with two variables per model according to
the number of events (18 deaths, yielding 6 events per covariable).
With CRP as the only covariable, lower IGF-1 (p = 0.011) as well
as higher CRP predicted higher mortality.
Again, a major limitation of this study is the low number of
participants and consequently relatively few events during follow-
up. The authors appropriately limited the number of covariables
in the survival models, although from this follows instead a high
risk of residual confounding. Furthermore, the large variety of
statistical methods used for testing associations between variables
make results less clear and exposes the analysis to the multiple
testing problem. For example, baseline associations to CRP were
tested using students t-test (for differences in IGF-1 levels between
CRP categories), logistic regression (for adjusted analysis) and
Pearson correlation.
1.4.3 Qureshi 2002
In a study investigating the association of nutritional status and
inflammation and other comorbidities to mortality, Qureshi et
al [111] measured IGF-1 levels in 128 prevalent HD patients.
Nutritional status indices included subjective global nutritional
assessment (SGNA) and anthropometric markers and serum al-
bumin. Patients followed for 36 months with 57 deaths. IGF-1
below median (170 ng/mL) was associated with higher mortality
(logrank p <0.01). In multivariable cox, parameters that exhibited
non-proportional hazards were excluded and IGF-1 was not in the
final model.
This study has a somewhat larger sample size that the ones above,
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but a major limitation to inference based on the results is the
absence of multivariable adjusted models for IGF-1. Baseline
associations between IGF-1 and other variables were not reported.
1.4.4 Hung 2005
Hung et al [104] measured IGF-1 and other nutritional markers
[albumin, subjective global assessment (SGA)] as well as markers
of inflammation (IL-6, IL-1b, TNF, serum amyloid A and CRP)
in 158 prevalent HD patients. Patients with obvious signs of acute
infection were excluded, follow-up was 36 months and 31 patients
died during this time. Covariables included dialysis adequacy
(kt/V), age, sex, dialysis vintage, coronary artery disease (CAD),
SGA and DM.
Variables were dichotomized into high and low-risk fractions re-
spectively, which for IGF-1 was the lowest tertile (<32.6 ng/mL).
IGF-1 in the lowest tertile was associated with an odds ratio
for mortality of 1.6 (95% CI 0.47-5.43, p = 0.45) when adjusted
for age, sex, DM, kt/V and dialysis vintage. In the fully ad-
justed models SGA and CRP remained predictive of mortality
and adding both these markers to the model improved model
likelihood ratio compared to including either. Of the variables
listed above, IGF-1 was positively associated with albumin and
diabetes and negatively with TNF, serum amyloid A and dialysis
vintage.
As in some of the previously mentioned studies, the number of
events were not sufficient for the number of covariables included
in survival analysis (5.2 events per covariable in the minimally
adjusted models), again making both type I and type II errors
more likely. Testing of model assumptions are not stated in the
article.
1.4.5 Kalousova 2012
With the chief aim of studying PAPP-A and mortality in HD,
Kalousova et al also measured IGF-1 levels in 261 prevalent HD
patients [112]. During 5 year follow-up 146 patients died. Uni-
variable Cox proportional hazards models were used for overall
mortality and death due to infection or cardiovascular causes,
respectively. IGF-1 was associated with all types of mortality in
univariable analysis (p < 0.001 for overall mortality) but, follow-
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ing a backwards exclusion method, IGF-1 was not included in
adjusted models.
1.4.6 Beberashvili 2013
Beberashvili [113] studied the interaction between IGF-1 levels and
inflammation (CRP, TNF) in 96 prevalent HD patients followed
for up to four years, during which 48 patients died. Survival
analysis utilized Cox proportional hazards models with adjustment
for age, gender, DM status, dialysis vintage and history of past
cardiovascular disease. IGF-1 was converted into an age and sex
adjusted standard deviation score (SDS). An SDS score below
median was not associated with increased mortality in crude (OR
1.5, 95% CI 0.73-3.07) or adjusted model, but for the multiplicative
interaction term of IGF-1 SDS below median and IL-6 above
median there was a statistically significant association to survival
in both crude (OR 4.27, 95% CI 2.10–8.68, p < 0.001) and adjusted
(OR 3.32, 95%CI 1.58–6.97, p = 0.002) models. Similar results
were seen for cardiovascular mortality.
In this study, the sample size was small and the number of events
insufficient (six events per variable when including the three non-
reference categories of the interaction term) for the multivariable
analysis performed. It should also be noted that adjustment
variables included age and sex, and since IGF-1 SDS was already
derived from the same variables, there may be over-adjustment
for these parameters.
1.4.7 Jia 2014
Jia et al measured IGF-1 in 365 CKD patients, including 115 in
HD, 92 PD and 158 CKD stage 5 not on dialysis [114]. Follow up
was 5 years follow-up and 28% (n ca 131) patients died during this
time. Survival was analyzed Cox proportional hazard models for
multivariable adjustment and and renal transplantation included
as a competing risk. When adjusted for calendar year of inclusion,
age, sex, DM, CVD, IL-6, and poor nutritional status (SGA
>1), higher IGF-1 at baseline was associated with lower all-cause
mortality when including all 365 CKD patients (HR, 0.57; 95%
CI, 0.32 to 0.98) and when including only HD patients, but not
when only PD patients were included.
In this study, baseline IGF-1 levels were negatively associated
to age, DM, CVD history, PEW, IL-6, and osteoprotegerin and
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positively- to serum phosphate, serum calcium, body fat mass,
bone mineral density, and fibroblast growth factor-23.
In a subset of patients, a follow-up IGF-1 was measured after 1
year. IGF-1 increased after initiation of dialysis in both patients
starting on PD and patients starting on HD. Mortality rate was
increased in patients with persistently low or decreasing IGF-1
concentrations compared with those who had persistently high or
increasing IGF-1 concentration.
This was the largest study to date reporting data on IGF-1 and
mortality in ESRD (N = 365), although CKD stage 5 patients not
on dialysis was also included (n on HD or PD = 207). Survival
analysis utilizing the full cohort (N = 365) had a sufficient number
of events (16 events/covariable) for the adjusted models but the
number of deaths in subgroups were not reported. A limitation of
this study is the pooling of data from different cohorts, introducing
a risk of bias due to differences between studies. However, this
may to some extent be ameliorated due to mean IGF-1 levels
being similar in patients on PD (187.2 ± 75.3 mkg/L), HD (191.3
± 93.9 mkg/L) and the total number of participants (191.9 ±
90.5 mkg/L). Further, the authors also report risk estimates in
the different subgroups.
1.4.8 Nilsson 2016
This study is part of the thesis [105]. Briefly, 265 HD patients were
followed for a minimum of three years and 134 deaths occurred
during follow-up [105]. IGF-1 was categorized into low or non-
low based on tertiles and predicted mortality in both crude and
adjusted models. Adjustment for confounders was incremental in
a series of Cox proportional hazards models with the full model
including age, sex, diabetes mellitus, cardiovascular disease, heart
failure, high-sensitivity CRP (hs-CRP), serum creatinine and
serum albumin. The number of events per variable in the statistical
models ranged from 13 to 67, which was deemed sufficient. Testing
of model assumptions was not reported. A major limitation of this
study was the lack of body composition- or nutritional parameters.
1.4.9 Other cohorts
Carrero at al [115] reported associations between IGF-1 and
thyroid hormone levels in ESRD. They found positive correlations
to triiodothyronine (T3) and free T3 and a negative correlation to
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Table 1.4: Characteristics cohort studies on PAPP-A and mor-
tality in dialysis
Author Year Population N
Kalousova 2004 Prevalent HD 40
Etter 2010 Prevalent HD 170
Kalousova 2012 Prevalent HD 261
Kalousova 2014 Prevalent HD with DM 1255
Nilsson 2017 Incident HD and PD 286
thyroxin-binding globulin, but did not report on the association
between IGF-1 and mortality.
1.4.10 Summary of studies on IGF-1 levels and
outcomes in ESRD
The two previous studies on IGF-1 and outcomes in ESRD that
were adequately powered [112,114] showed an association between
lower IGF-1 and higher mortality in ESRD. However, Kalousova
et al [112] did not report multivariable adjusted results for IGF-1
on mortality and in the study by Jia et al [114] pooling of different
cohorts, whose participants had different stages of kidney disease,
is an important limitation. Our study [105] addresses some of
these limitation through including only incident HD patients,
providing sufficient power for the analyses made and presenting
results adjusted for potential confounders. Nevertheless, we did
not have access to data on body composition and concerns about
residual confounding therefore remain.
1.5 PAPP-A as a biomarker in ESRD
The association of PAPP-A to outcomes in ESRD has been inves-
tigated in a few relatively small studies and one larger study on
prevalent HD patients, where PAPP-A levels are increased and
associated with all-cause mortality [77,112,116,117]. Characteris-
tics of these studies is presented in Table 1.4 and a summary of
results from the same studies is shown in Table 1.5.
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Table 1.5: Summary of results from cohort studies on PAPP-A
and mortality in dialysis
Author Crude model Adjusted model
Kalousova 2004 Higher PAPP-A non-survivors -
Etter 2010 - OR 1.009–1.088†
Kalousova 2012 HR 1.002–1.345 HR 1.060–1.444
Kalousova 2014 HR 1.04-1.19 HR 1.06-1.23
Nilsson 2017 - HR 0.99–1.41
Hazard ratios are per standard deviation increase, except
for those marked †, which are hazard ratios per unit increase.
1.5.1 Kalousova 2004
In 2004 Kalousova et al reported preliminary results [116] from
a study on prevalent HD patients published in 2012 [112]. The
authors found differences in PAPP-A levels between survivors
(n=18) and non-survivors (n=22), with median PAPP-A at 26.8
(IQR 21.6-36.8) vs 20 (IQR 14.9-26.6) mU/l, and Mann-Whitney U
test p-value = 0.034. The low number of participants and the lack
of censoring analysis are obvious limitations of this preliminary
analysis, although lack of censoring may be less problematic since
all participants were followed for the duration of the 20 months
follow-up period.
1.5.2 Etter 2010
Etter et al [117] studied PAPP-A levels in relation to outcomes in
170 prevalent HD patients from the the monitor! trial (N = 174).
PAPP-A was lower in survivors (Mdn 20, IQR 15–25) compared to
non-survivors (Mdn 28, IQR 19–35, Mann– Whitney U p-value =
0.008) and in multivariable adjusted analysis using logistic regres-
sion (using 159 complete cases with 21 deaths). Higher PAPP-A
was associated with increased risk of death (OR 1.048, CI 1.009–
1.088, p = 0.015). Adjustment (with the standard simultaneous
entry method) was for age, sex, number of comorbidities, dialysis
vintage, IL-6, CRP, PTH, calcium-phosphate product, and total
serum cholesterol. In addition Kt/V was added to the model in
a separate sensitivity analysis (n = 110 with 17 deaths, OR not
reported, CI 1.014–1.111, p = 0.01). This yields 2.1 events per
variable indicating that lack of power may be a problem in this
study, which is acknowledged by the authors. Odds ratio (OR) is
not reported for the univariable association between PAPP-A and
mortality. Cardiovascular mortality and morbidity were stated as
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secondary outcomes by the authors but not reported in results,
perhaps due to the limited number of events.
1.5.3 Kalousova 2012
Kalousova et al [112] studied the association between PAPP-A
levels and outcomes in 261 long-term HD patients followed up for
5 years with censoring at renal transplantation (n = 52). In a
multivariable Cox proportional hazards analysis including cardiac
troponin-I, albumin, creatinine, retinol, age, DM and CVD and
with stratification for dialyzer membrane type (low- or high-flux),
PAPP-A levels predicted all-cause mortality (n = 138) and death
due to infection (n = 36) but not cardiovascular death (n = 70).
The preliminary results of this study, with short-term follow-up,
were published separately in 2004 [116].
Selection of covariables for the adjusted models was done in three
steps: First, the authors selected biochemical parameters that
were associated with outcome in univariable analysis. These were
then entered into a multivariable analysis eliminating parameters
using backward exclusion. The remaining independent biochemi-
cal predictors were then entered together with demographic and
clinical variables in yet another stepwise backwards exclusion
procedure. The use of a stepwise procedure for variable selec-
tion is flawed due to risk overfitting and inflated p-values, and
puts the results of the adjusted models in study into question
[118]. Additionally the number of events per variable was 3.3-13
(depending on outcome) in the first step (with only biochemical
variables), 2.3-8.6 in the second step and 4.5-17 in the final multi-
variable model. Thus, the study was under-powered for analysis
of separate outcomes for cardiovascular death and especially for
death due to infection, leading to increased risk of type I and
type II errors. Notably, lack of power may have influenced the
stepwise selection procedure. However, PAPP-A was associated
to mortality in univariable analysis (HR 1.161, CI 1.002–1.345)
and with the log-rank test PAPP-A levels in the fourth quartile
(>30.8 mIU/l) was associated with worse survival compared to
values in the first to third quartiles.
1.5.4 Kalousova 2014
Kalousova et al investigated the association between PAPP-A and
cardiovascular events in diabetic hemodialysis patients [77]. The
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data was from a previous randomized controlled trial investigating
atorvastatin in 1255 patients with type 2 diabetes mellitus study
(the 4D study) including subjects on hemodialysis for less than 2
years and with the primary endpoint defined as a composite of
cardiac death, non-fatal myocardial infarction (MI) or stroke.
The analysis of PAPP-A in relation to outcomes aimed to investi-
gate the association to different outcomes and consequently the
combined cardiovascular events (CVE) category from the origi-
nal 4D study, sudden death, MI, stroke, all-cause mortality and
deaths due to infection were analyzed separately. In some of the
prediction models presented, PAPP-A was entered as a continuous
variable and hazard ratios computed per standard deviation. In
others, PAPP-A quartiles were used.
The authors found that higher PAPP-A levels were associated with
increased risk of all-cause mortality as well as with the combined
cardiovascular events endpoint. Elevated PAPP-A levels were also
associated with stroke, sudden cardiac death and death due to
infection, but not with myocardial infarction.
A total of 1098 patients, who had a PAPP-A measurements
available, were included in the analysis and 534 of these persons
died during follow-up (141 from sudden cardiac death and 114
due to infection). Regarding non-fatal outcomes, 398 patients
had CVE, 169 had MI and 85 suffered a stroke. This yields 5.7-
36 events per variable in the fully adjusted models, depending
on outcome (or 4.7-30 events per variable if PAPP-A quartiles
are used). Consequently, the study may be somewhat under-
powered for separate analysis of stroke, but sufficient for the other
outcomes.
In multivariable analysis, adjustment was for age, sex, smoking
status, body mass index, atorvastatin treatment, systolic blood
pressure, dialysis vintage, coronary artery disease, and levels of
hemoglobin, hemoglobin A1c, albumin, phosphate, creatinine and
total cholesterol. It may be noted that adjusting for both CAD
and the treatment thereof (atorvastatin treatment), as well as risk
factors for CAD such as cholesterol levels may lead to violation
of the assumption of no multicollinearity required for the Cox
proportional hazards model, especially since PAPP-A levels were
associated with both CAD and cholesterol levels. Testing of model
assumptions was not reported.
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1.5.5 Nilsson 2017
This study is part of the thesis [119]. Briefly, PAPP-A levels,
inflammation biomarkers and body composition indices were mea-
sured in 286 incident dialysis patients. During follow-up 60 months
follow-up, 86 patients died and in an adjusted model including
cardiovascular risk factors and body composition, higher PAPP-A
was associated with mortality. This association was in part con-
founded by inflammation. Multivariable models included 9 to 11
covariables, resulting in 7.8 to 9.6 events per variable. It should
be noted that this is short of the minimum 10 events per variable
recommended [108].
1.5.6 Summary of studies on PAPP-A levels
and outcomes in ESRD
To summarize, PAPP-A has been investigated in relation to out-
comes in prevalent HD patients in a few studies but not in incident
dialysis patients (prior to our work included in this thesis). Due to
high short-term mortality after dialysis initiation [120], studies on
prevalent patients are not representative for the incident dialysis
population.
The association of PAPP-A to all-cause mortality is consistent
in the studies reviewed above and analyses have been adequately
powered in two of these. However, some authors have also aimed
to study the association of PAPP-A to other outcomes such as
cardiovascular death, cardiovascular events and death due to
infection. Most of the studies have been under-powered for such
analysis and used methods for covariable selection that are not
recommended [112,117]. A single study was adequately powered to
analyze other outcomes than all-cause mortality in multivariable
models [77]. Here, the authors found that higher PAPP-A levels
predicted a combined cardiovascular events endpoint, sudden
cardiac death and death due to infection, but not myocardial
infarction. There was also an association to stroke but due to an
inadequate number of such events the evidence on this point must
be considered weak.
Based on the above, there is a lack of research on PAPP-A as a
predictor in incident dialysis patients and a scarcity of adequately
powered studies in prevalent dialysis patients. The association
of PAPP-A to all-cause mortality in prevalent dialysis patients
would benefit from being replicated using multivariable models
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with a thoughtful approach to covariable selection. The association
between PAPP-A levels and death due to infection is intriguing
but has only been reported in one study with adequate power
and should therefore also be replicated if possible. A conservative
approach to selection of covariables may enable analysis of separate
outcomes in smaller cohorts. Some of these issues were addressed
in one of the studies included in this thesis, which used incident
dialysis patients and where covariable selection was based on
previous knowledge [119].
1.6 Potassium dysequilibrium in CKD
Under normal conditions, the kidneys maintain potassium home-
ostasis, which is important for physiological functions such as
acid-base balance, cardiac electrical conduction, smooth muscle
tone and neuronal signaling [121,122]. The main regulatory mech-
anism for potassium excretion depends on the mineralocorticoid
hormone aldosterone, which stimulates excretion of potassium in
the renal tubules and collecting ducts [6]. CKD increases the risk
of hyperkalemia and high potassium levels in CKD are associated
with increased mortality [123]. Medications interfering with the
renin-angiotensin-aldosterone system (RAAS) are also associated
with increased risk of hyperkalemia [124,125].
Rates of hyper- and hypokalemia differ between studies [124–126]
and reports on dyskalaemia incidence and risk factors in the
broad healthcare setting are few and based on North American
data [123,125,127]. In paper III, we investigated hyper- and
hypokalemia in a Swedish healthcare system including associations
to renal function and medications affecting the RAAS.
1.6.1 Studies on hyperkalemia incidence
Previous studies have reported on hyperkalemia incidence in the
North American healthcare setting [123,125,127]. Chang et al
investigated hyperkalemia in patients undergoing blood pressure
testing and found three year incidence proportions of 10.8% for
K >5.0 and 2.3% for K>5.5 [127]. Similarly, Einhorn et al in-
vestigated hyperkalemia in healthcare users with one or more
inpatient hospital visits and found that as many as 13.7% had
hyperkalemia ≥ 5.5 mmol/L within one year [123]. In paper
III we found that during three years follow-up, approximately
7.0% had mild- and 2.5% had moderate/severe hyperkalemia and
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that one in three of these cases had recurrence of hyperkalemia.
Chang et al and Einhorn et al also investigated hyperkalemia
recurrence and found comparable numbers, although it should be
noted that these studies were on different populations and with
different definitions of recurrence than ours [123,127].
After the publication of our paper III, Thomsen et al described
the occurrence, risk factors and clinical outcomes of elevated
potassium levels in a Danish population-based cohort study [128].
A total of 157,766 patients with CKD diagnosis were included.
The one-year cumulative incidence of hyperkalemia was 4.8% for K
>5.0 and 2.1% for K >5.5. The corresponding three-year incidence
was 22% and 10%, respectively. Risk factors for hyperkalemia
included DM, heart failure, ACEi, potassium supplements and
spironolactone. The authors found worse outcomes for CKD
patients with hyperkalemia.
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Chapter 2
Research aims
The overall aim of this thesis was to increase knowledge about
hormonal alterations in CKD and their consequences, focusing
on CVD, mortality and growth hormones. We therefore tested
cross-sectional associations between different hormones and known
risk factors for CVD, with the aim of elucidating pathophysio-
logical processes contributing to high mortality in CKD. We also
analyzed longitudinal associations between blood hormone levels
and outcomes, to assess these hormones as markers of increased
mortality risk.
2.1 Aims of each sub-study
In paper I [105] we investigated the association between IGF-
1 and mortality as well as its association to inflammation and
albumin. Serum hs-CRP and serum albumin were considered
potential confounders and the association between serum IGF-1
levels and mortality, above established cardiovascular risk factors,
was assessed.
In paper II [119] we investigated another component of the
GH/IGF-1 system, PAPP-A, in relation to mortality and CVD
in HD patients. Due to the lack of previous research on incident
HD patients, an additional aim of the study was to present data
on PAPP-A and mortality for incident as opposed to prevalent
dialysis patients. Based on theoretical and previously observed
links between PAPP-A, body composition DM and inflammation,
a further aim was to test if the hypothesized association between
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PAPP-A and mortality would be modulated by these factors. We
also reported results on associations between PAPP-A and CVD
risk factors.
In paper IV [129], we sought to add to existing research on
the association between PAPP-A and mortality in prevalent HD
patients and specifically to test our previous exploratory finding
that inflammation and DM and modified the effect of PAPP-A
on mortality. In addition, we attempted to replicate a previously
observed association between PAPP-A and inflammatory markers.
In paper V we tested whether combining a function measurement
of muscle strength (handgrip strength, HGS) with a biochemical
nutritional marker (plasma IGF-1 levels) would have a stronger
association to mortality in CKD than either marker alone.
In paper III [130], we originally planned to estimate hyper-
kalemia risk after initiation of mineralocorticoid receptor antago-
nist (MRA) treatment in a large healthcare cohort and specifically
to study the influence of renal failure on that risk. Instead, we de-
scribed hyperkalemia and hypokalemia risk in general (ie not only
in MRA treatment) and identified risk factors for these events,
including reduced renal function and MRA treatment.
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Chapter 3
Subjects and methods
3.1 Subjects and study designs
3.1.1 Örebro risk marker cohort
This cohort was based on biobank samples collected routinely from
patients starting HD at a single dialysis clinic (Örebro University
hospital) during the years 1991–2009. Those with prior history
of dialysis treatment or renal transplantation were excluded and
the study population was 265 persons. In 2013, data on survival
time and comorbid conditions were retrieved from diagnoses in
the Swedish National Patient Register. Demographic data, time
to renal transplantation, cases of regained renal function and
cause of renal failure were collected from the Swedish Renal
Registry. Follow-up was 3 years and survival time was censored
at renal transplantation or regained renal function. This cohort
was utilized in paper I. Additional results from this cohort are
presented in chapters 3 and 4 and covered by the original ethics
approval from the Regional Ethical Review Board in Uppsala
(Dnr 2009/082).
3.1.2 Malnutrition, inflammation, and atheroscle-
rosis (MIA) cohort
This ongoing cohort was started in 1994 and includes CKD stage
5 (GFR <15 mL/min) patients planned for initiation of dialysis
treatment at the Karolinska University Hospital at Huddinge,
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Sweden [80]. Exclusion criteria were: Age <18 years or >70
years, clinical signs of acute infection, active vasculitis or liver
disease. Patients were sampled in proximity to the start of renal
replacement therapy (either HD or PD) and followed until death or
renal transplantation. Body composition was measured using dual-
energy X-ray absorptiometry (DEXA). This cohort was utilized
in paper II.
3.1.3 Mapping of inflammatory markers in
chronic kidney disease (MIMICK-1 and
MIMICK-2) cohorts
The MIMICK-1 cohort was utilized in paper IV and includes
prevalent HD patients with a minimum of 3 months of HD treat-
ment from the Karolinska University Hospital at Huddinge, Stock-
holm, Sophiahemmet, Danderyds Hospital and Uppsala Academic
Hospital. Inclusion was from October 2003 through March 2004.
Patients undergoing regular HD treatment at any of the units
(n=254) were invited to participate. Six patients declined, and
one patient with human immunodeficiency virus infection was
excluded. The original aim of this study was to assess variabil-
ity of inflammatory parameters over time and after 12 weeks
follow-up, eleven patients were excluded from the cohort due to
insufficient baseline clinical data; seven were excluded due to lack
of hs-CRP measurements and one patient who had died was also
excluded from further analysis. The remaining 228 patients were
followed for 5 years and causes of death retrieved from death cer-
tificates. Ninety-two of these had frozen plasma samples available
for analysis and were included in paper IV.
The MIMICK-2 cohort was designed similarly to MIMICK-1, but
included prevalent PD patients at Karolinska University Hospital
and Danderyds Hospital, Stockholm, Sweden [131]. All patients
had been treated with continuous ambulatory peritoneal dialysis
or automated peritoneal dialysis for a minimum of 3 months before
inclusion. Recruitment was from March 2008 to April 2011. Of
82 patients originally included in MIMICK-2, blood samples for
IGF-1 analysis were available for 70 patients, constituting part of
the material for paper V.
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3.1.4 Stockholm CREAtinine Measurements
(SCREAM) cohort
The SCREAM cohort data includes residents in the region of
Stockholm who had serum creatinine measured during 2006–11.
The study reported in paper III includes adult individuals (>17
years of age) accessing healthcare in 2009 with at least one am-
bulatory measurement of serum creatinine in the preceding year
and with at least one follow-up potassium test during three years
follow-up, amounting to a total of 364 955 persons. Renal function
was estimated using the CKD-EPI creatinine-based equation and
comorbid conditions defined from previous diagnoses in the health-
care system, using ICD codes. Concomitant medications were
retrieved from complete information of drugs dispensed at Swedish
pharmacies [132]. Outcomes were defined as follows: Hypokalemia
was defined as potassium <3.5 mmol/L; hyperkalemia as potas-
sium >5 mmol/L and further classified as moderate/severe if >5.5
mmol/L.
3.1.5 Other cohorts
In paper V, data from multiple CKD cohorts was combined and
included 75 CKD 3-4 patients (PRIMA cohort), 361 incident dial-
ysis patients (MIA-cohort, described above), 70 prevalent PD pa-
tients (MIMICK-2 cohort, described above) and 179 prevalent HD
patients (MIMICK-1 cohort, described above) with a total of 685
CKD patients. IGF-1 levels and HGS values were dichotomized
at cut-offs determined by receiver operating characteristic (ROC)
curve analysis. These categories were then combined and tested
for prediction of death (n = 208) during the 5 year follow up time.
In the PRIMA cohort, patients with CKD were recruited from the
renal outpatient clinic of Karolinska University Hospital. Exclu-
sion criteria were: Clinical signs of acute infection, active vasculitis,
or liver disease. This cohort has been described previously, for
the initial 50 patients included [133].
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3.2 Laboratory methods
3.2.1 Immunometric assays of growth hormone
axis components
In the Örebro risk marker cohort as well as the MIA and MIMICK
cohorts, IGF-1, IGF-1 binding protein-3 (IGFBP-3) were ana-
lyzed using immunometric assays on an Immulite 1000 Analyzer
(Siemens Healthcare Diagnostics, Los Angeles, CA, USA). In the
MIA and MIMICK cohorts, PAPP-A was measured using ELISA
(R&D Systems, Minneapolis, USA).
3.2.2 Other methods
Handgrip strength was assessed with a Harpenden Handgrip Dy-
namometer (Yamar, Jackson, MI, USA). Measurements were
made in the dominant hand for patients without an arteriovenous
(AV)-fistula and otherwise in non-AV-fistula arm. Values were
normalized using measurements from healthy subjects. In preva-
lent HD patients (MIMICK-1 cohort), the measurements were
made post dialysis.
In the MIA cohort, GFR was determined using the mean of renal
urea and creatinine clearances during a 24-hour urine collection,
which is considered a reasonably accurate estimate of GFR in
patients starting on dialysis [134,135].
Dual-energy x-ray absorptiometry was used in the MIA cohort
(paper II and V). Measurements performed using a DPX-L
device (Lunar Corp, Madison, WI).
3.2.3 The drawing of blood
In the MIA and MIMICK2 cohorts, blood samples were collected
after an overnight fast while in the MIMICK1 cohort samples were
drawn before the dialysis session after the longest interdialytic
period. Plasma samples were stored at –70°C.
In the Örebro risk marker cohort, samples were retrieved up to 11
days prior to dialysis initiation and stored frozen at -20°C if not
analyzed immediately. Storage time may slightly affect levels of
IGF-1 in stored samples [136]. Consequently, to test the effects
of storage time on serum IGF-1 values, a variable for the period
of inclusion was computed and mean IGF-1 values in patients
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Figure 3.1: Storage time and IGF-1 levels
recruited during the different time periods compared (Figure
3.1).
3.3 Register data
In the Örebro risk marker cohort (paper I), register data was
used. Demographic data, time to renal transplantation, cases of
regained renal function and cause of renal failure were collected
from the Swedish Renal Registry, which is maintained by the
Swedish Society of Nephrology. International Classification of
Diseases (ICD) codes for comorbid conditions were retrieved from
inpatient diagnoses in the Swedish National Patient Register,
which has been validated for a number of diagnoses and has
complete coverage of inpatient care since 1982 [137,138]. Time
until death and cause of death were retrieved from the Swedish
Cause of Death Register. In the SCREAM cohort [139] (paper
III), two additional registers were utilized: Regional register data
from Stockholm county council was used for retrieval of ICD codes
and the Swedish Pharmaceuticals Registry was used for data on
medication dispensation [132].
While registers provide cheap access to data, there are a number
of challenges associated with use of register data. Naturally, the
researcher has no control over the data entry procedure and it is
therefore difficult to assess the quality of data. Since diagnoses are
sometimes put in error or before conditions are fully confirmed,
there is also a risk of misclassification that may introduce bias in
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Figure 3.2: Comparison of classifications of diagnoses based on
different registries in 265 hemodialysis patients
study results. An advantage to the Swedish national registers is the
complete coverage of all deaths and dispensed medications and of
all diagnoses entered in the local healthcare administrative systems.
They are therefore not dependent on a single investigator catching
and noting diagnoses and are therefore likely to have a high
sensitivity for known medical conditions. This is illustrated in Fig
3.2, which shows a comparison of classifications using the national
patient register and the Swedish renal registry, respectively, based
on data used for the Örebro risk marker cohort (paper I). It
can be noted that the Swedish renal registry has a lower number
of positive classifications in all disease categories. For paper I
we used the national patient register data for classification of
comorbid conditions.
3.4 Statistical methods used in the dif-
ferent studies
In paper I, we assessed the distribution of baseline variables
by visual inspection of density- and Q–Q plots (Fig 3.3). The
Normal or Non-Normal distribution of data then guided the se-
lection of descriptive point- and variance estimates, ie mean and
SD for Normal data and median and IQR for Non-Normal data.
The method used for hypothesis testing or comparison of base-
line parameters in two groups was also selected based on these
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assessments, whereby we used Student’s t-test for Normal dis-
tributed continuous variables and Wilcoxon–Mann–Whitney test
for Non-Normal data.
Although the method of visual inspection or other testing of nor-
mality is often used for statistical method selection, this approach
is flawed [140]. As an example, see Fig 3.3, which displays data
on IGF-1 levels used in paper I. The non-transformed IGF-1 values
(panels A and C) are approximately normally distributed, but
do not display a perfect fit to normality. It is apparent that the
decision if one should accept the non-transformed data or not
has some measure of subjectivity to it. Note that square-root
transformation (panels B and D) in this case improves fit to
normality. However, although such transformation would perhaps
optimize performance of certain statistical tests, it would also
impair interpretation of results.
Furthermore, the testing of normality (irrespective of the method
used - visual or by significance testing) introduces an extra level
of testing which by itself contributes to the uncertainty of the
final results. In other words, the tests used for assessing normality
are subject to the risks of type I and type II error. It can be
argued that any increase in statistical power gained through using
a parametric method on the basis of such assessment is at risk
of being lost due to the extra “layer” of testing. Alternative
approaches include: Firstly, deciding on the Normal- or Non-
Normal distribution of variables based on previous literature.
This removes the formal testing from the current analysis, but
if existing evidence is conflicting on this point some measure of
uncertainty will be introduced anyway and influence the validity
of the study results. Such an approach may be suitable if there is
ample pre-existing data on the distribution of a certain parameter.
The log-scale of CRP may serve as an example. The second
approach is to a-priori decide to use non-parametric methods.
This eliminates the step of normality testing altogether, but may
result in loss of statistical power due to inherent properties of non-
parametric statistics. This approach may be suitable if sample
size is relatively large and the variable in question cannot be
assumed to have Normal distribution based on previous studies.
It has the further benefit of simplicity - the same statistics can be
used for all variables of the same type. As an example, in paper
II we used quantile regression models for describing associations
between baseline variables. When it comes to descriptive statistics
it is probably useful to show both mean (SD) and median (IQR)
[141].
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Figure 3.3: Density plots and Q-Q plots for testing distribution
of IGF-1 levels
The focus on p-values has been discussed and challenged in scien-
tific press [142] and it should be noted that for some statistical
methods such as quantile regression, the confidence interval of
estimates as well as the p-values are computed using bootstrap-
ping methods and therefore subject to some variation between
different runs of the same data. Although we did in some of our
papers try to put less emphasis on a specific cut-off for statistical
significance, reviewers did not approve.
For survival analysis we used the popular Cox proportional hazards
model in paper I, II and IV. To be valid, these models must
be tested for a number of assumptions, the foremost of which is
proportional hazards. Different methods exist for such assessment,
and in line with the discussion on normality above, it can be
argued that such testing is also subject to uncertainty. In fact,
statements on testing of model assumptions are often omitted
from scientific publications. As exemplified in one of the papers
on IGF-1 and mortality cited above, Himmelfarb et al tested the
proportional hazards assumption using a product term between
time and the explanatory variables, although it was not stated
which other assumptions were tested [106]. In our paper II,
non-proportional hazards mandated the use of a time-varying
coefficient for CVD, providing further information that CVD was
predictive of mortality in day 0-400 after dialysis initiation, but not
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thereafter. Again, “non-parametric” methods for survival analysis
are available and in paper IV, we utilized quantile regression as
a complementary analysis. This has the added benefit of giving
more easily interpretable statistics (ie the proportion of individuals
surviving past a certain time point).
In paper I, we used dichotomization of IGF-1 levels to categorize
participants into “low” and “non-low” groups. This practice may
be intuitively appealing, for example to facilitate interpretation,
being able to characterize a group with relative IGF-1 deficiency
and to remove the effects of outliers. However, it is generally
not recommended due to loss of statistical power, risk of spuri-
ous findings, reduced comparability to other studies and risk of
missing non-linear relationships [143]. In paper II, we tested
associations between PAPP-A and cardiovascular risk factors in a
cross-sectional analysis using a quantile regression method, which
may be a preferable approach to reducing the effect of outliers
without the inherent disadvantages of dichotomization.
Selection of explanatory variables is another important aspect of
statistical model and method selection. Automated methods for
exclusion and inclusion of explanatory variables exist (such as
step-wise forward or backward exclusion), but are fraught with
problems [144,145]. For example, only a select set of variables are
entered into the model in the first place and unmeasured variables
that could have influenced the model selection procedure may
be absent. Sometimes, explanatory variables for multivariable
analysis are selected based on their association with the outcome
in univariable analysis, a method we used in paper I. However,
this is generally not recommended [146]. A priori selection of
explanatory variables may be a more reasonable approach. Then
at least it is possible to argue for and against including certain
variables based on what is already known. This, of course, does
not eliminate the problem of unmeasured confounding. Since the
number of explanatory variables is limited by statistical power
(sample size and number of events) it is often advantageous to
a-priori remove factors that are not regarded as confounders.
Certain theories may help in eliminating some confounders from
the model selection in a structured manner and using Directed
Acyclic Graphs is such a method [147].
Over-adjustment may also also present a problem. For example
the commonly used eGFR estimate of renal function includes
age in its calculation, and if one also uses Age as such as a
explanatory variable, it will be entered two times in the model.
Another example is albumin, which is lower in inflamed states,
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and sometimes used in conjunction with CRP, thus introducing a
dual adjustment for inflammation. One approach, if uncertainties
on what variables to include in analysis, is to present sensitivity
analyses utilizing a somewhat different set of explanatory variables,
to assess the consistency of findings.
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Chapter 4
Results and discussion
4.1 IGF-1
In the first published work (paper I) [105], we found that pa-
tients with low IGF-1 levels had worse outcomes in hemodialysis.
In multivariable analysis on mortality, including adjustment for
cardiovascular risk factors (age, sex, DM, heart failure and his-
tory of CVD) and biochemical markers (hs-CRP, s-creatinine,
s-albumin), we found that low IGF-1 remained associated with
higher mortality risk when adjusted for these factors.
In paper V, we hypothesized that combining a function measure-
ment of muscle strength (HGS) with a biochemical nutritional
marker (plasma IGF-1 levels) would have a stronger association
to mortality in CKD than either marker alone. We found that
patients in the combined low IGF-1 and low HGS category had
increased mortality rate compared to the other categories and that
this association was robust when adjusted for CVD risk factors
(Framingham’s CVD risk score, previous CVD, smoking) inflam-
mation (hs-CRP, plasma albumin) and markers of PEW [SGA,
lean body mass index (LBMI)]. The predictive utility of IGF-1
was somewhat enhanced but still weak in the low HGS group (area
under the curve changed from 0.6 to 0.66). A major limitation to
this study was the use of pooled data from different cohorts with
diverse characteristics that may impact both predictors (HGS,
IGF-1) and outcome. Indeed, median HGS was markedly lower
in prevalent dialysis patients compared to the other groups. To
somewhat ameliorate these methodological concerns, a term for
dialysis status (on dialysis vs not on dialysis) was included as a
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Table 4.1: Multivariable regression model on IGF-1 levels in 265
hemodialysis patients
Variable Estimate CI [5%, 95%]
Intercept 230 [190, 270]
hs-CRP, mg/L -0.15 [-0.25, -0.051]
Female -30 [-45, -14]
Age, years -1.1 [-1.7, -0.57]
Diabetes mellitus -15 [-31, 0.29]
Linear regression with adjustment for all variables shown.
Abbreviations: hs-CRP, high-sensitivity C-reactive protein.
covariable in the regression analysis on mortality.
Our results showing an association between IGF-1 levels and
mortality are in line with two adequately powered previous studies
on IGF-1 and outcomes in ESRD [112,114]. However, Kalousova
et al [112] did not report multivariable adjusted results for IGF-
1 on mortality and in the study by Jia et al [114] pooling of
different cohorts, whose participants had different stages of kidney
disease, is an important limitation. Paper I addresses some of
these limitations through including only incident HD patients,
providing sufficient power for the analyses made and presenting
results adjusted for potential confounders. Nevertheless, in paper
I we did not have access to data on body composition and concerns
about residual confounding therefore remain. Thus, we provide
novel results in the form of survival models adjusted for important
confounders and with validity for incident HD patients. Further,
in paper V we show that low HGS is associated with mortality
in a mixed CKD-ESRD population and that adding IGF-1 levels
may perhaps improve prediction in the group with low HGS.
4.1.1 Factors associated with IGF-1 levels
In paper I, low IGF-1 was associated with female sex, lower
IGFBP-3 levels, inflammation (higher hs-CRP, lower albumin)
and lower creatinine (which may be regarded as a marker of PEW
in this population) but not with CVD, age or DM. Multivariable
analysis on IGF-1 levels was not reported in the paper but is
shown here in Table 4.1.
In paper V, IGF-1 was positively correlated with muscle function
(HGS), muscle mass (LBMI) and BMI while it was negatively asso-
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Table 4.2: Associations between IGF-1 levels and selected vari-
ables in dialysis
Parameter Nilsson 2016 Chen Jia 2014 Hung 2005 Fernandez 2002
Age 0 Neg Neg 0 Neg
Female Neg 0 0 0 NA
DM 0 Neg Neg Pos NA
CVD 0 Neg Neg 0 NA
CRP Neg Neg NA 0 Neg
IL-6 NA Neg Neg 0 NA
Creatinine Pos Pos NA NA 0
Albumin Pos Pos NA Pos Pos
PEW NA Neg Neg Neg NA
HGS NA Pos NA NA NA
PEW was defined as SGA >1. Abbreviations: Pos, positive; Neg, negative;
zero (0) denotes no association.
ciated with SGA >1, supporting its role as a marker of nutritional
status and protein-energy wasting. Consequently, IGF-1 was also
positively associated with other markers influenced by nutrition
and PEW such as albumin, creatinine and calcium-phosphate
product. IGF-1 was negatively correlated with cardiovascular risk
factors (age, DM, smoking, history of CVD, mean blood pressure
and Framingham’s CVD risk score) as well as inflammatory mark-
ers (IL-6, hs-CRP, TNF). In multivariable analysis, low IGF-1
was independently associated with lower HGS, lower LBMI, lower
albumin and higher Framingham’s CVD risk score.
Table 4.2 shows associations between IGF-1 levels and selected
variables in cohort studies reviewed in section 1.4. The studies by
Himmelfarb et al [106], Beberashvili et al [113] and Qureshi et al
[111] are not included, since they did not report on associations
to IGF-levels. Multivariable analysis was reported only in the
studies by Chen et al (paper V) and Fernandez-reyes et al [110].
Low IGF-1 was associated with inflammation (higher hs-CRP) in
both of the studies included in this thesis. Data on the association
between IGF-1 and inflammation has been reported by others.
Jia et al [114] found in unadjusted analysis that IL-6 levels were
weakly and negatively associated with IGF-1 levels; similarly,
Fernandez-reyes et al [110] reported a negative correlation to
CRP while Hung et al [104] found no association to IL-6. Taken
together, these results indicate lower IGF-1 levels in inflammatory
states. Figure 4.1 shows the quantile regression coefficients for
hs-CRP on IGF-1 levels in the data set used for paper I and
provides some additional information on the association between
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Figure 4.1: Association between hs-CRP and quantiles of IGF-1
in 265 hemodialysis patients
IGF-1 and inflammation. It can be noted that the regression
coefficient becomes increasingly negative with increasing quantiles
of IGF-1, leading to the interpretation that it is perhaps mainly
IGF-1 levels in the higher end of the spectrum that are reduced
in inflamed dialysis patients.
Although CVD was somewhat more prevalent in the “low IGF-1”
group in paper I, the differences were not statistically significant.
In paper V IGF-1 was negatively correlated to CVD and inde-
pendently associated with CVD risk factors. Others have found
no association [104] or a negative association [114]. Thus, based
on somewhat weak evidence, IGF-1 levels appear to be reduced in
dialysis patients with CVD, possibly due to its association with
CVD risk factors.
Higher age was associated with lower IGF-1 levels in paper V,
and in the data presented in Table 4.1, although the difference
between “low” and “non-low” IGF-1 groups were not statistically
significant when tested using Student’s t-test in paper I. Others
found a negative association [110,114] or no association [104].
Thus, higher age appears to be associated with lower IGF-1 levels
in dialysis patients.
In our first study [105], female sex was associated with lower
IGF-1 levels. However, in paper V and in the two additional
studies reporting on sex differences [104,114] there was no such
association.
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Figure 4.2: IGF-1 and IGFBP-3 levels in 265 hemodialysis
patients
Although DM was more common in the low IGF-1 group in paper
I, the difference between groups was not statistically significant.
However, in paper V and in the study by Jia et al [114] there was
a negative association between DM and IGF-1 levels. Conversely,
in the study by Hung et al, the association was positive in [104].
Thus, results on the association between DM and IGF-1 in dialysis
patients are inconsistent.
Markers of PEW (lower creatinine, lower LBMI and SGA >1)
were associated with lower IGF-1 in unadjusted analysis in both
our studies, although statistical significance was not reached for
SGA >1 in adjusted analysis. It may be argued, however, that
the multivariable model in paper V may have over-adjusted for
PEW due to including multiple PEW-related markers (LBMI,
SGA, HGS, and arguably albumin). Others have consistently
found negative associations between IGF-1 and PEW [104,114].
It should be noted that IGF-1 levels correlate strongly to levels of
IGFBP-3. Figure 4.2 shows the correlation between IGF-1 and
IGFBP-3 levels at baseline in the Örebro risk marker cohort. The
strong correlation between these two markers signals that they do
not contain differential prognostic information and furthermore, if
included in the same regression model may cause problems with
collinearity. It also indicates that the IGF-1 to IGFBP-3 ratio,
which is sometimes used to measure “free IGF-1” is not likely
to discriminate disease states or prognosis better than the total
IGF-1 values in patients starting HD.
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To summarize, our findings that IGF-1 levels are lower in inflam-
matory states and PEW are in line with previous dialysis cohort
studies. The negative association to age reported in paper V was
consistent with previous findings, as was the positive association
to albumin. DM and sex were not consistently associated with
IGF-1 levels. Thus, inflammation, age, PEW and perhaps DM
should be considered potential confounders when analyzing effects
of IGF-1 levels on mortality in dialysis.
4.2 PAPP-A
In paper II we studied the association between PAPP-A levels
and mortality in patients starting dialysis [119]. We also described
potential confounding and modifying effects of DM, body com-
position and inflammation on this association. In cross-sectional
analysis, PAPP-A levels were associated with lean tissue index
(LTI) and high-sensitivity C-reactive protein (hs-CRP) but not
with fat tissue index (FTI) or history of CVD. In survival analy-
sis, higher PAPP-A levels were associated with higher mortality,
although there was a confounding effect of inflammation on this
association. Interestingly, when the analysis was stratified by
diabetes status, higher PAPP-A was associated with mortality in
diabetic patients but not in those without diabetes. This finding
was robust when adjusted for inflammation and other confounders
and was further explored in another cohort in paper IV (see
below). There are no previous studies on the association between
PAPP-A and mortality in incident dialysis patients and, impor-
tantly, due to the high early mortality after initiation of dialysis
[120], studies on prevalent patients are not representative for the
incident dialysis population. Thus we provide novel evidence that
PAPP-A is associated with mortality when sampled at the initia-
tion of dialysis and results are therefore applicable to assessment
of prognosis in patients planned for dialysis treatment.
In paper IV, we studied PAPP-A levels and mortality in prevalent
HD patients. Based on findings in our previous work on incident
dialysis patients, we hypothesized that concomitant DM and
inflammation would modulate the association between PAPP-A
and mortality. In univariable Cox proportional hazards analysis
higher PAPP-A was associated with increased risk of mortality.
In multivariable analysis, explanatory variables selected on the
basis of prior knowledge were entered, including age and sex in
the minimally adjusted model and then in addition DM, BMI and
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hs-CRP in a model regarded as “fully” adjusted for confounders.
Finally, to assess the association between PAPP-A and mortality
beyond established risk markers, adjustment was also made for
dialysis vintage and cardiovascular risk factors and we found that
the association remained statistically significant in all models.
There were 37 deaths during follow-up, 16 of which were deaths
due to cardiovascular causes. This equates to 12.3, 6.6 or 3.4
events per variable, depending on model. The model adjusted
for only age and sex is therefore sufficiently powered, while the
other models should be regarded with caution. For interaction
testing, a limited set of explanatory variables was used and we
found statistically significant positive interactions between PAPP-
A levels and DM. Subsequent analysis stratified on DM status
indicated that PAPP-A predicted mortality only in diabetic HD
patients. Death due to cardiovascular causes was analyzed as a
secondary outcome and was sufficiently powered in the univariable
model, in which PAPP-A levels failed to predict the outcome.
There is limited research on PAPP-A in prevalent HD patients.
Most studies include a mix of diabetic and nondiabetic patients
and show that PAPP-A levels are associated with all-cause mor-
tality [112,116,117]. In the largest available study on PAPP-A as
a marker of mortality in HD only patients with DM were included
[77] and in paper II we observed that in incident HD patients,
the association between PAPP-A and mortality appeared stronger
in those with DM [119]. In paper IV we replicated these find-
ings and provided novel evidence that there is effect modification
from DM also in prevalent HD patients. The distinction between
prevalent and incident patients is important due to the high early
mortality after dialysis initiation [120], which contributes to dif-
ferences in characteristics. Notably, the proportion of patients
with DM is likely to be lower in prevalent compared to incident
HD, due to DM being a risk factor for mortality. Also, there may
be differences in types of CVD mortality between incident and
prevalent HD patients [120]. Thus, results from incident cohorts
are not automatically valid in cohorts including prevalent patients
and vice versa.
In paper IV, we found no interaction between PAPP-A and CRP,
which is in contrast with paper II [119] and some previously pub-
lished research [61]. Potential explanations for these discrepancies
in results include differences between prevalent and incident HD
patients, a limited sample size and large variance in CRP levels,
which may yield insufficient power to detect weak interactions.
It remains unclear if the association of PAPP-A to mortality in HD
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is due to an association with cardiovascular mortality. Although
increased PAPP-A activity may have a causative role in cardiovas-
cular disease [148], it should be considered that rather than being
causal in the atherosclerotic process, elevated plasma levels of
PAPP-A may represent local up-regulation and escape of PAPP-
A into the circulation due to tissue injury or inflammation [25].
Association between circulating levels of PAPP-A and outcomes
therefore do not necessarily support a causative role of PAPP-A in
CVD. In line with this, Kalousova et al [112] found that PAPP-A
was associated with all-cause mortality and death due to infection
but not with cardiovascular mortality and in a subsequent study
found an association with sudden death, stroke and death due to
infection, but not with risk of myocardial infarction [77]. Similarly,
there was no association between PAPP-A levels and cardiovascu-
lar mortality in paper IV (the limited power for analyzing this
specific outcome should be noted) and we found no association
between history of CVD and PAPP-A levels in paper II or in
the data used for paper IV (linear regression estimate of CVD
on PAPP-A levels at baseline = 0.19, CI: -0.056-0.44, p-value =
0.2). The question therefore remains which pathophysiological
process underlies the association between higher PAPP-A levels
and worse outcomes in dialysis patients.
A number of important limitations apply to our results on PAPP-
A in dialysis patients. There was a relatively small number of
participants in both studies, resulting in low statistical power
restricting the number of independent variables in the statistical
models, which may lead to residual confounding. Limited statisti-
cal power also increases the propensity for type I and type II error.
However, a high event rate somewhat balanced the relatively small
number of participants and results in the fully adjusted models
were consistent with models using a more conservative number
of independent variables. An additional limitation was that our
definition of DM included both type 1 and type 2 DM, which
precludes differentiation between these two conditions. Further,
the post-hoc analysis of existing cohort data and stored samples
may contribute to publication bias if all findings are not published.
To ameliorate this, hypotheses and statistical models were for-
mulated prior to analysis. Acknowledging these limitations, our
results from paper II and IV are nevertheless concordant and
in line with previous evidence [77] of higher PAPP-A levels being
associated with increased all-cause mortality in dialysis patients
with DM.
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4.3 Hyperkalemia and hypokalemia
We originally planned to study hyperkalemia in mineralocorticoid
users in the Stockholm CREAtinine Measurements (SCREAM)
project but we decided instead to study the incidence and risk fac-
tors for potassium disturbances. In paper III we therefore aimed
to describe the incidence, severity and recurrence of hyperkalemia
and hypokalemia and to identify risk factors for dyskalaemia
among demographic factors, comorbid conditions and concomi-
tant medications.
We found that both hypokalemia and hyperkalemia were common.
Hyperkalemia occurred in 7% of participants, comparable to
studies from US healthcare [123,127]. The frequency of potassium
testing was as expected a determinant of dyskalaemia risk, also
described previously [127]. Other risk factors for hyperkalemia
included diabetes mellitus, higher age, lower eGFR, previous
myocardial infarction, heart failure or use of renin angiotensin-
aldosterone system inhibitors (RAASi). Notably, female sex was
associated with lower risk of hyperkalemia and higher risk of
hypokalemia. The same pattern was seen for younger age, higher
eGFR and use of loop/thiazide diuretics. The association of
dyskalaemia related to different medications [6,123,127,149], and
comorbid conditions [123,150–153], has been described previously.
Reduced kidney function was one of the strongest risk factors for
hyperkalemia, in line with previous studies [151,152,154–156]. The
use of creatinine based eGFR in our analysis is therefore especially
important, due to lack of awareness for CKD and underutilization
of ICD diagnoses in healthcare [157,158].
Limitations to this study include that data was lacking for some
potential risk factors of hyperkalemia, such as blood pressure and
body mass index, as well as its retrospective design. External
validity is limited by the data being from a single large city region
in Sweden, and findings may therefore not be applicable in other
healthcare systems. There is also a risk of residual confounding
due to unmeasured factors and confounding by indication, the
latter precluding separating the risk of hyperkalemia associated
with use of certain medications from risk due to the underlying
condition for which the patient was treated.
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Chapter 5
Summary and
conclusions
In paper III on hyper- and hypokalemia, we evaluate the potas-
sium testing in a large healthcare system, analyze the rates and
likelihood of recurrence of both mild and moderate/severe hyper-
kalemia during a 3-year period. We show that both hyper- and
hypokalemia is common in healthcare. Hyperkalemia was espe-
cially common in the presence of comorbidities, foremost in those
with poor kidney function. Our results highlight the multitude
of risk factors involved, including age, sex, diabetes, hyperten-
sion and cardiovascular disease. The use of RAASi remained
strongly associated with occurrence of hyperkalemia after adjust-
ment for comorbid conditions. Vigilant potassium monitoring
may therefore be mandated in these conditions.
We add to existing evidence pointing to IGF-1 as a marker associ-
ated with worse outcomes in CKD by showing that this association
is applicable to incident HD patients and are robust when ad-
justed for important confounders. We also show that low HGS
is associated with mortality in a mixed CKD-ESRD population
and that adding IGF-1 levels possibly improves in the group with
low HGS. Further, we conclude that inflammation, age and PEW
should be considered potential confounders when analyzing effects
of IGF-1 levels on mortality in dialysis.
Previous research shows that PAPP-A levels are associated with
outcomes in prevalent HD patients who have DM but it is less
clear whether this is also true in patients about to start dialysis
treatment and in nondiabetic HD patients, respectively. We
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provide novel evidence that the association between PAPP-A and
mortality in dialysis patients is modulated by concomitant DM
and that there is effect modification from DM in both incident
dialysis patients and prevalent HD patients. This implies that
results concerning the association of PAPP-A to survival that
are based on patients with DM may not be generalizeable to
dialysis patients without DM. In addition, inflammation and body
composition (FTI) were identified as potential effect modifiers for
the association between PAPP-A and mortality.
Although disturbances in GH-IGF-1 signalling in CKD could
hypothetically contribute to for example CVD and thereby con-
tribute to higher mortality, interpretation of blood levels of these
hormones is not straightforward. For example circulating levels
of IGF-1 and PAPP may not reflect alterations in their activity
on the target cell. Rather, increases may be compensatory to
decreased IGF-1 signalling or secondary to confounders associated
with CVD, such as inflammation, or in the case of PAPP-A tissue
damage may lead to up-regulation and release into the circula-
tion. Knock-out models could be more reliable but are limited to
non-human subjects and knock-outs that are not tissue specific
do not reflect changes in a specific organ such as the vasculature
or heart. Also, it may not be appropriate to extrapolate from
such models to ESRD where GH/IGF-axis is disturbed in other
ways. It is also possible that the effect of GH/IGF-1 signalling is
modulated by synergistic factors making it turn good or bad for
vascular health depending on context. In fact, it appears likely
that a hormone system with such pleiotropic effects would be
contextually dependent, with myriad regulating factors on organ-
and cellular level. Therefore, caution should be observed when
interpreting our findings in relation to pathophysiology. This,
however, does not preclude the possible usefulness of GH/IGF-1
axis hormones as biomarkers for identifying detrimental conditions
such as PEW and in assessing prognosis in CKD.
5.1 Applicability of results
The utility of blood hormone levels in revealing underlying patho-
physiological conditions of importance in ESRD is limited by
the generally weak link between hormone pathophysiology and
blood hormone levels. Systemically acting hormones (where hor-
mone action is more tightly related to systemic levels), such as
IGF-1, may be less limited by this than locally acting factors
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(like PAPP-A), although local IGF-1 action is regulated by other
components of the GH-IGF-1 axis, such as IGFBPs and PAPP-A.
As markers of mortality risk, they must be compared to existing
clinical biomarkers such as troponin and brain natriuretic peptide.
However, blood biomarkers are easily retrieved, especially in HD
patients who can be sampled during the HD session. If markers
of clinical conditions, such as undernutrition and PEW, can be
identified, they may serve as early warning signs and mandate
interventions. In this context, GH-IGF-1 hormones could be of
importance since associations between IGF-1 and multiple mark-
ers of nutrition and PEW have previously been shown. If IGF-1 is
superior to for example albumin as a marker of these conditions,
providing more evidence on the association between IGF-1 and
mortality is relevant, since markers used for initiating interven-
tions should ideally be associated with outcomes. It should be
noted that the only large randomized controlled trial on IGF-1
replacement therapy in ESRD was not successfully executed, and
that GH/IGF treatment as an option in PEW cannot be ruled
out entirely [103]. However, the complex regulation of IGF-1
action through IGFBPs and other players indicate that treating
relative IGF-1 deficiency may not be as simple as adding more
of the hormone. Other possible interventions include nutritional
counseling and increased physical activity.
The interpretation of PAPP-A levels is even less straightforward
than for IGF-1. From a pathophysiological standpoint, PAPP-A is
associated to atherosclerotic disease processes, but its function is
local IGF-1 regulation. Indeed the enzyme is normally membrane-
bound, and the association between blood levels and tissue PAPP-
A activity is unclear. However, similarly to cardiac troponin
PAPP-A may be useful as a biomarker for cardiovascular risk,
hypothetically through release from injured vasculature tissue,
unrelated to its pathophysiological action. If up-regulation of
PAPP-A is first required it can be reasoned that it may have
other attributes that cardiac troponin, which does not require
prior up-regulation to be detected at injury.
5.2 Future perspectives
There are a number of components of the GH-IGF-1 axis that
could be of interest as biomarkers in patients with chronic kidney
disease. For example, the IGF-1 binding proteins as well as GH
receptor levels are dysregulated in renal failure and could be tested
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as markers for conditions such as PEW or as prognostic biomarkers
[84,97,99]. However, as has been discussed, plasma biomarkers
are generally limited by weak associations to pathophysiological
conditions underlying increased morbidity and mortality in the
CKD population, and few such markers presently have clinical
utility. Novel techniques for detecting and studying modifiable
risk factors in dialysis patients should therefore be explored.
5.2.1 Improving the utility of PAPP-A as a
marker of cardiovascular disease
Although evidence points to a role of membrane bound PAPP-A
in atherosclerotic disease, the link between serum concentrations
of PAPP-A and its function in the pathophysiological pathways
of atherosclerosis is tentative. Serum PAPP-A may reflect tissue
damage causing release of PAPP-A into the circulation rather that
up-regulation of the membrane-bound enzyme. Measurement of
cell-membrane bound PAPP-A could therefore be a better proxy
of its role in promoting cardiovascular disease, but is limited
by the difficulty of obtaining tissue samples in human subjects.
Interestingly, serum levels of PAPP-A are highly influenced by
heparin administration. This may be due to heparin binding to
the glucoseaminoglycan binding site, releasing membrane-bound
PAPP-A into the circulation [77].
Based on the above, it can be proposed that elevation of PAPP-A
after heparin administration could be a more accurate marker of
cardiovascular dysfunction than are baseline serum levels, better
reflecting the role of membrane bound PAPP-A in the atheroscle-
rotic process. Hemodialysis treated persons have a high prevalence
of cardiovascular disease and are routinely administered heparin
at the start of each dialysis session. This provides a promising
opportunity to study the association between heparin-induced
elevation of PAPP-A and cardiovascular disease.
Atherosclerotic disease is rampant in ESRD, where existing tools
for predicting cardiovascular disease such as electrocardiogram,
troponin levels and exercise stress testing perform poorly. Better
prognostic markers are therefore needed for identifying individuals
that may benefit from intensified risk factor treatment or inter-
ventional procedures [159]. Heparin-induced increase in PAPP-A
could prove to be a novel, powerful and easily measured biomarker
for cardiovascular disease risk in hemodialysis patients.
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Chapter 6
Populärvetenskaplig
sammanfattning
Tillväxthormon (eng Growth Hormone, GH) reglerar omsättnin-
gen av fett, kolhydrater och proteiner i kroppen. Hormonet
påverkar även hjärta och blodkärl. GH produceras i hjärnan
och får levern och andra organ att frisätta “Insulin-like Growth
Factor 1” (IGF-1), vilket är det hormon som främst förmedlar
effekterna av GH i kroppen. IGF-1 regleras i sin tur av olika
IGF-1-bindande proteiner i blodet och av en molekyl vid cellytan
som kallas Pregnancy Associated Serum Protein-A (PAPP-A).
Hos personer med njursvikt föreligger rubbningar i flera olika hor-
monsystem, bland annat tillväxthormonsystemet. Vi har studerat
hur nivåer av IGF-1 och PAPP-A i blodet hos dialysbehandlade
är kopplade till faktorer som ökar risken för hjärt- kärlsjukdom
och till den kraftigt ökade dödlighet som ses vid dialysbehandling.
Våra resultat visar lägre nivåer av tillväxthormon (IGF-1) hos
dialysbehandlade som är äldre, lider av undernäring eller har låg
muskelmassa och hos dem som är inflammerade. Låga nivåer
IGF-1 i blodet kan därför vara tecken på sådana tillstånd och vid
analys av IGF-1 nivåer hos dialysbehandlade i samband med veten-
skapliga studier behöver man ta hänsyn till dessa sk “förväxlings-
faktorer”. Vi ser dock att även när man tar hänsyn till dessa
faktorer är låga nivåer IGF-1 förknippade med sämre överlevnad
i bloddialys. Eventuellt kan mätning av handgreppstyrka tillsam-
mans med nivåer av IGF-1 vara av värde för att bättre bedöma
prognosen för personer med njursvikt.
Liksom för IGF-1 påverkas nivåerna av PAPP-A i blodet av
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inflammation och muskelmassa. I motsats till IGF-1 är dock dessa
faktorer förknippade med höga nivåer av PAPP-A vilket i sin tur
är kopplat till ökad dödlighet hos patienter som behandlas med
dialys. Våra resultat visar att detta gäller för dem som skall starta
dialys såväl som för dem som redan haft bloddialys en tid samt
att kopplingen mellan PAPP-A nivåer och dödlighet föreligger
främst hos dialysbehandlade som också har diabetes.
Vi har även studerat förekomsten av låga och höga nivåer av
kalium hos personer som har kontakt med sjukvården och sett att
avvikande kaliumnivåer är vanligt samt att det ofta är återkom-
mande hos personer som någon gång haft ett avvikande kali-
umvärde. Högt kalium visade sig vara särskilt vanligt hos dem
med nedsatt njurfunktion, diabetes, hög ålder, hjärtsjukdom och
vid användning av vissa läkemedel. Kvinnligt kön medförde lägre
risk för högt kalium men istället ökad risk för lågt kalium, ett
mönster som även sågs hos yngre, de med god njurfunktion och
vid användning av vätskedrivande läkemedel. Dessa resultat visar
på vikten av att vara medveten om riskerna för kaliumrubbingar
hos personer som har kontakt med sjukvården och att följa upp
viss läkemedelsbehandling med noggrann provtagning.
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Chapter 8
Erratum
8.1 Paper I
In table 1, hs-CRP is noted in the “variables” column as presented
using mean (SD), but the figures diplayed represent median (IQR).
In table 1, IGFBP-3 is noted in the “variables” column as presented
using median (IQR), but the figures diplayed represent mean (SD).
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